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Endothelial Cytotoxicity Mediated by Serum Antibodies to
Heat Shock Proteins of Escherichia coli and
Chlamydia pneumoniae
Immune Reactions to Heat Shock Proteins as a Possible Link Between
Infection and Atherosclerosis
Manuel Mayr, MB; Bernhard Metzler, MD; Stefan Kiechl, MD; Johann Willeit, MD;
Georg Schett, MD; Qingbo Xu, MD, PhD; Georg Wick, MD
Background—Growing evidence suggests that an immunological reaction against heat shock proteins (HSPs) may be
involved in atherogenesis. Because HSPs show a high degree of amino acid sequence homology between different
species, from prokaryotes to humans, we investigated the possibility of “antigenic mimicry” caused by an immuno-
logical cross-reaction between microorganisms and autoantigens.
Methods and Results—Serum antibodies against the Escherichia coli HSP (GroEL) and the 60-kDa chlamydial HSP
(cHSP60) from subjects with atherosclerosis were purified by use of affinity chromatography. Western blot analyses and
competitive ELISAs confirmed the cross-reaction of the eluted antibodies with human HSP60 and the bacterial
counterparts. The cytotoxicity of anti-GroEL and anti-cHSP60 antibodies was determined on human endothelial cells
labeled with
51Cr. A significant difference (40% versus 8%) was observed in the specific
51Cr release of heat-treated
(42°C for 30 minutes) and untreated cells, respectively, in the presence of these anti-HSP antibodies and complement.
This effect was blocked by addition of 100 mg/mL recombinant GroEL. In addition, seropositivity against specific
non-HSP60 Chlamydia pneumoniae antigens is more prominent among high–anti-HSP titer sera than low-titer sera.
Conclusions—Serum antibodies against HSP65/60 cross-react with human HSP60, cHSP60, and GroEL; correlate with the
presence of antibodies to C pneumoniae and endotoxin; and mediate endothelial cytotoxicity. These findings suggest
that humoral immune reactions to bacterial HSPs, such as cHSP60 and GroEL, may play an important role in the process
of vascular endothelial injury, which is believed to be a key event in the pathogenesis of atherosclerosis. (Circulation.
1999;99:1560-1566.)
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R
ecent evidence indicates that the first steps of athero-
sclerosis are inflammatory in nature.1 The discovery of
macrophages, T lymphocytes, dendritic cells, and mast cells
in atherosclerotic lesions; the detection of HLA class II
antigen expression; and the finding of secretion of several
cytokines point to the involvement of immune inflammatory
mechanisms in the pathogenesis of atherosclerosis.1,2 Further-
more, atherosclerotic lesions contain immunoglobulin depos-
its and complement, including the lytic “membrane attack
complex” C5b-C9, strongly suggesting the involvement of
complement activation in atherogenesis.3 Bacterial and viral
infections have been implicated as potential initiating factors.
Infections are known to increase blood viscosity, cause
hypercoagulability, and influence the serum lipid profile. In
infections by Gram-negative bacteria, endotoxin may also
contribute to endothelial cell production of free radicals,
which may oxidize LDL.4 With respect to potential infectious
causes involved in atherosclerosis development, attention has
focused on Helicobacter pylori, Chlamydia pneumoniae, and
cytomegalovirus.5
A putative antigen maintaining this inflammatory process
in the arterial wall must be ubiquitous and present at young
age, explaining the overall prevalence of this disease even in
young people.6 Heat shock proteins (HSPs) serve as a
promising target for inducing an immunological attack on
endothelial cells and may constitute the missing link between
the incriminated microorganisms and autoimmunity.
HSP65/60 is a major antigen recognized during various
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1560bacterial infections,7 but stress protein induction also occurs
in eukaryotic cells after viral infections.8 Data from our
laboratory have shown that atherosclerotic lesions can be
induced in normocholesterolemic rabbits by immunization
with recombinant mycobacterial HSP65 (mHSP65)9 and in-
hibited by simultaneous immunosuppressive treatment (Dr
Metzler, unpublished data, 1998). Interestingly, mHSP65-
reactive T cells were enriched in atherosclerotic lesions
compared with peripheral blood even in animals that had
received a high cholesterol diet without mHSP65 immuniza-
tion.10 Furthermore, levels of serum antibodies to mHSP65
were significantly increased in clinically healthy human
subjects with carotid atherosclerosis compared with those
without lesions, and these increased antibody levels were
independent of common risk factors.11
Methods
Definition of Clinical and Laboratory Methods
Human sera were derived from the Bruneck Study, a large,
population-based study on the epidemiology and origin of athero-
sclerosis and arterial disease. The Bruneck Study population com-
prises an age- and sex-stratified random sample of men and women
who are 40 to 79 years old (baseline evaluation in 1990). Carotid
atherosclerosis was quantified by means of high-resolution duplex
ultrasound as extensively described previously.11–13 Sera for the
current evaluation were drawn as part of the first follow-up study in
1995.
Blood samples were taken from the antecubital vein after subjects
had fasted and abstained from smoking for $12 hours. Clinic and
laboratory parameters were examined by standard methods as
described previously.12,13 Antibodies against mHSP65 and Esche-
richia coli lipopolysaccharides (L 2880, Sigma Chemical Co) were
determined by ELISAs following an established protocol.11 All
“high-titer sera” (HTS) had anti-mHSP65 antibody titers of
$1:1280, whereas “low-titer sera” (LTS) did not exceed 1:160
(cutoff point for optical density, 0.2 at 410 nm).
Affinity Chromatography of Anti-HSP Antibodies
Purification of serum anti-HSP antibodies was performed following
an established method.14 Briefly, immunoglobulins of pooled HTS
were precipitated by a standard (NH4)2SO4 procedure and incubated
in a chromatography column with 2 mL agarose gel beads (Affi-Gel
Kit, Biorad) coupled with 3 mg recombinant mHSP65, GroEL, or
cHSP60. Specific immunoglobulins were recovered by 20 mmol/L
HCl acid elution, pooled, and equilibrated with PBS, pH 7.2.
Anti-HSP antibody titers of purified immunoglobulins were similar
to original HTS (1:1280), whereas unbound immunoglobulin had no
measurable HSP antibody titer (,1:20).
Western Blotting
This procedure was also described previously.14 In brief, samples
were diluted 1:20 (vol/vol) in sample buffer containing 5%
2-mercaptoethanol, 15% glycerol, 3% SDS, and 0.1 mol/L Tris, pH
6.8, and separated on a 12% polyacrylamide gel under reducing
conditions. Blots were probed with anti-HSP antibodies (5 mg/mL),
including purified anti-HSP antibodies, HTS, and the monoclonal
antibody II-13 (a gift from Dr R.S. Gupta, Hamilton, Canada).
Reactions were visualized by an enhanced chemiluminescence de-
tection kit (Amersham) after incubation with a peroxidase rabbit
anti-human or anti-mouse immunoglobulin conjugate.
Endothelial Cytotoxicity Assays
Human umbilical vein endothelial cells (HUVECs) were cultured
and identified as described previously.14 Human aortic endothe-
lial cells were purchased from Cascade Biologics. For antibody-
mediated cytotoxicity, endothelial cells were heat stressed at
42°C for 30 minutes to induce HSP60 expression, whereas control
cells remained at 37°C. The assay was performed following an
established protocol14 and is described in brief in the legend of
Figure 5. Supernatant was analyzed for
51Cr-radioactivity (Amer-
sham) in a gamma counter (Wallac-Wizzard Automatic Gamma
Counter). Both human, including LTS and unbound immunoglob-
ulin fraction, and monoclonal mouse antibodies, including mAb
anti–a-actin (catalog No. 1148818, Boehringer, Mannheim,
FRG), mAb anti-CD3 (catalog No. M756, Dakopatts), and mAb
anti-bHCG 58 prepared in our laboratory, were used as controls
in the cytotoxicity tests. Blocking experiments were performed by
addition of anti-HSP antibody preincubated with 100 mg/mL
soluble recombinant GroEL for 1 hour at room temperature.
Specifically released radioactivity was determined by calculation
according to the following formula:
51Cr release in the presence of
antibodies minus spontaneous release divided by maximal release
minus spontaneous release. Maximal release was obtained by
adding 5% Triton X-100 to the cultures. Spontaneous release was
determined in the presence of complement without antibodies and
did not exceed 15% of maximal release.
Statistical Analysis
The association between anti-HSP antibody titers (category #160
versus $1280) and atherosclerosis/cardiovascular disease was as-
sessed by means of unconditional logistic regression analysis.
ANOVA was performed when .2 groups were compared. Paired
Student’s t test was used to assess differences between 2 groups. A
value of P,0.05 was considered significant.
Specific Tests for C pneumoniae
IgG antibodies to C pneumoniae were measured by 3 different test
systems: SeroCP-IgG (Savyon Diagnostics Ltd), microimmunofluores-
cence (MIF) antibody kit (Labsystems Oy), and chlamydial IgG
recombinant lipopolysaccharide (LPS) ELISA (Medac). The analyses
were performed and calculated according to manufacturers’ instructions.
In contrast to the former test systems that used elementary bodies, a
recombinant chlamydial LPS antigen was used for precoating in the last
ELISA kit.
Results
Clinical Characterization of Serum Samples
A previous analysis in the Bruneck Study population has
shown that increased antibody titers to HSPs were indepen-
dent of classic risk factors for atherosclerosis (n5867).11 On
comparison of subjects with antibody titers #160 and those
with titers $1280, the latter group faced a 2- to 3-fold
increased risk of prevalent carotid atherosclerosis (unadjusted
OR, 2.44; 95% CI, 1.56 to 3.80; P,0.0001; adjusted OR,
2.48; 95% CI, 1.58 to 3.89; P,0.0001). Similar results were
obtained when prevalent cardiovascular disease was used as
the outcome variable (unadjusted OR, 3.63; 95% CI, 1.66 to
7.94; P50.0013; adjusted OR, 4.35; 95% CI, 1.93 to 9.84;
P50.0004). In this analysis, cardiovascular disease encom-
passes myocardial infarction, ischemic stroke, transient ische-
mic attack, and symptomatic peripheral artery disease.
Forty sera with known high or low anti-mHSP65 titers
(HTS $1280/LTS #160) were selected from this population
for the present study. No significant difference in classic risk
factors for atherosclerosis was observed between these 2
groups (Table 1). In addition, HSP antibody titers did not
show a significant correlation with C-reactive protein and
blood granulocyte count.
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Against HSPs
The specimens (HTS/LTS) were tested for their reactivity
against the E coli HSP60 GroEL and the HSP60 of C tracho-
matis, which is nearly identical to the HSP of C pneumoniae
(amino acid sequence homology, '97%). Comparison of these
antibody titers to the anti-mHSP65 titer revealed an overall
correlation of '90% for GroEL and 75% for cHSP60. The
correlation coefficient between the titers of anti-GroEL and
anti-cHSP60 antibodies was 0.7 (Figure 1).
We then purified these polyclonal anti-HSP antibodies
from pooled HTS by affinity chromatography. The eluted
antibodies were capable of recognizing their human and
bacterial counterparts, as demonstrated by Western blot
analyses (Figure 2). However, the strongest reaction was
consistently found with the HSP of E coli, GroEL. Ovalbu-
min, free of HSP but with an identical molecular weight of 60
kDa, served as negative control and did not interact with the
purified antibodies, although it was still recognized by HTS
because of anti-ovalbumin antibodies, as confirmed by
ELISA experiments. As positive control, a monoclonal anti-
body to HSP60 (II-13) stained all types of HSPs but not
ovalbumin. The cross-reactivity and specificity of the various
purified antibodies were confirmed by competitive ELISA
experiments (Figure 3). Complete inhibition was achieved
only with the HSP used for antibody purification. For
anti-GroEL and anti-mHSP65 antibodies, inhibition with
cHSP60 was significantly less effective compared with the
bacterial counterparts (P,0.05).
Reactivity of Serum Antibodies to Non-HSP60
Bacterial Antigens
Serum samples were assayed for C pneumoniae IgG antibod-
ies by use of an MIF test and 2 commercial ELISA kits. The
purified anti-HSP antibodies did not appear to cross-react
TABLE 1. Clinical Characterization of Subjects With Low and
High Anti-HSP Antibody Titers
LTS HTS P*
Age, y 65.5610.7 63.1610.9 0.58
Male sex, % 70 70 1.00
Total cholesterol, mmol/L 6.2461.16 5.5560.87 0.11
LDL cholesterol, mmol/L 4.0361.00 3.4960.86 0.15
HDL cholesterol, mmol/L 1.4360.32 1.4960.35 0.68
Triglycerides, mmol/L 1.6860.19 1.6960.18 0.89
Body mass index, kg/m2 24.862.7 25.062.3 0.88
Hypertension, % 38 23 0.22
Smoking, % 30 8 0.32
Alcohol, g/d 44.0652.1 55.1643.4 0.56
Fasting glucose, mmol/L 5.4960.60 5.5460.48 0.85
Leukocyte count, 109/L 5.962.5 5.961.7 0.92
Granulocytes, 109/L 3.361.9 3.160.8 0.64
CRP, mg/L 2.667.1 2.563.1 0.84
ESR, mm/h 6.964.5 5.262.9 0.27
Hypertension indicates blood pressure $160/95 mm Hg; CRP, C-reactive
protein; and ESR, erythrocyte sedimentation rate. Data are mean6SD (n540)
or percentages.
*Statistical analyses were performed using Student’s t test and x2 test.
When Bonferroni adjustments were performed to control type I error for
multiple comparisons (n515), the value to be achieved for statistical signifi-
cance decreased to P,0.0033.
Figure 1. Correlation among serum antibodies to HSPs. Forty human serum samples with known high (M) or low (f) anti-mHSP65
titers were tested for their reactivity to GroEL and cHSP60 in standard ELISA procedure. First 2 scatter plots show correlation analyses
of these latter antibody titers to anti-mHSP65 titer. Data revealed correlation of '90% for GroEL (r250.87, P,0.001) and 75% for
cHSP60 (r250.56, P,0.001). Finally, relationship of 70% was found regarding seroprevalence of anti-GroEL and anti-cHSP60 antibod-
ies (r250.5, P,0.001). Note that in case of overlap, one symbol can represent more than one serum sample.
Figure 2. Western blot analyses of anti-HSP antibodies (Ab).
Puriﬁed recombinant mHSP65 (10 mg), human HSP60 (20 mg),
GroEL (5 mg), cHSP60 (20 mg), and ovalbumin (20 mg) were sep-
arated on 12% SDS-PAGE gels followed by transfer to nitrocel-
lulose membrane. Blots were incubated with puriﬁed human
anti-HSP antibodies, HTS, and monoclonal antibody to HSP60
for 2 hours at room temperature.
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tests revealed that seropositivity against non-HSP60 C pneu-
moniae antigens was more prominent among HTS than LTS
(Table 2). The seroprevalence of IgG antibodies among LTS
was 77% all together, but only 31% within this group were
considered highly positive in the SeroCP ELISA system. In
contrast, all HTS had detectable IgG antibodies; surprisingly,
77% were also highly reactive against C pneumoniae elemen-
tary bodies. The mean optical density for LTS was calculated
as 2.07, interpreted as positive. The mean optical density for
HTS reached 2.88, considered highly positive. MIF data
afforded a quantitative determination of IgG antibody re-
sponses in both groups. Sera with undetectable IgG titers
(,1:32) occurred more often among LTS, whereas medium-
(1:32) and high- (1:128) titer sera were more frequent among
HTS. Acute, primary infections with C pneumoniae could be
ruled out, because none of the serum samples showed a
positive reaction for IgM antibodies after absorption with
anti-human IgG. Data of the recombinant chlamydial LPS
ELISA correlated well with the MIF test and provided
clear-cut results: 54% of LTS were negative but about 55% of
HTS reached titers of $1:200. In parallel to elevated anti-
GroEL antibodies, we also detected a higher antibody prev-
alence against E coli LPS in HTS (Figure 4). Statistical
analysis revealed a significant correlation between anti-LPS
antibodies and anti-HSP titers (r50.59, P,0.001).
Endothelial Cytotoxicity
All purified anti-HSP antibodies exerted effective
complement-mediated endothelial cytotoxicity on stressed
HUVECs. A specific dose-dependent release of
51Cr from
heat-treated cells was observed in the presence of anti-GroEL
and anti-cHSP60 antibodies, with a dramatic increase after
antibody concentrations rose .25 mg/mL (Figure 5). Lysis
reached '70% in stressed endothelial cells, whereas an
average of only 10% of total radioactivity was released from
unstressed cells in the presence of anti-HSP antibodies. This
striking effect on stressed endothelial cells could be blocked
by the addition of 100 mg/mL recombinant GroEL (Figure 6).
Even the anti-cHSP60 antibody lost its cytotoxic potential
after preincubation with GroEL. Unbound immunoglobulins
from the affinity chromatographic procedure, LTS, and un-
related monoclonal antibodies evoked no significant cyto-
toxic effect. In preliminary experiments, anti-GroEL and
Figure 3. Competitive ELISA with anti-
mHSP65 antibodies (Ab), anti-GroEL
antibodies, and anti-cHSP60 antibodies.
Each antibody was preincubated with
different dilutions of mHSP65 (E), GroEL
(N), and cHSP60 (l), respectively, for 1
hour at room temperature and tested on
ELISA plates coated with 1 mg/mL of
same protein used for antibody puriﬁca-
tion. BSA (3), determined to be free of
HSPs, served as negative control.
TABLE 2. Determination of Anti-C pneumoniae IgG Antibodies
LTS HTS
Sero-CP ELISA, %
Negative 15 0
Borderline 8 0
Positive 46 23
Highly positive 31 77
MIF Test, %
Negative 54 8
1;32 38 69
1;128 8 23
rcLPS ELISA, %
Negative 54 15
Borderline 15 15
1;100 8 15
$1;200 23 55
Sero-CP indicates serology for C pneumoniae; rcLPS, recombinant LPS. IgG
antibodies to C pneumoniae antigens were measured by 3 different test
systems. Results show that immune reactions against C pneumoniae were
more frequent among HTS than LTS.
Figure 4. Comparison of anti-E coli LPS antibodies in low and
high anti-HSP titer sera. LPS tested to be free of contamination
with HSPs/GroEL was coated on ELISA plates in concentrations
of 2 mg/mL. Data revealed that serological response to LPS cor-
related signiﬁcantly with anti-GroEL titers (r50.59, P,0.001).
Error bar represents SEM.
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thelial cells in the presence of high concentrations of normal
human peripheral blood mononuclear cells at an effector-to-
target ratio of 1:50 via antibody-dependent cellular cytotox-
icity (data not shown). To determine whether such an
antibody-mediated cytotoxicity also occurs in arterial endo-
thelial cells, human aortic cells and HUVECs were cultivated
and treated in parallel. Although no significant difference in
the cytotoxic lysis between both types of endothelial cells
was found, anti-mHSP65 antibodies markedly induced
51Cr
release from heat-stressed cells (Figure 7). In addition, heat
stress treatment at 42°C for 30 minutes did not result in
endothelial cell necrosis or apoptosis (data not shown).
Discussion
We previously demonstrated a strong association between
sonographically detectable carotid atherosclerosis and high
levels of serum antibodies to mHSP65 in the Bruneck
Study population (n5867).11 Bacterial and viral infections
can induce immune reactions against HSPs, which may
serve as targets for autoimmune reactions.15 The anti-
mHSP65 antibodies react not only with mHSP65 but also
with human HSP60 and the bacterial counterparts of E coli
and C pneumoniae. Herein, we demonstrate that several
epitopes of bacterial HSPs seem to exhibit cross-reactive
antibody binding. These findings could signify a possible
involvement of infections in atherogenesis, because the
cross-reactive epitopes may contribute to the elevated
anti-mHSP65 antibodies in subjects with atherosclerosis.
The natural microbial flora may also influence such
immune reactions to various degrees, eg, GroEL of E coli.
However, competitive ELISAs indicate that some addi-
tional specific epitopes must exist.
Antibodies to mHSP65 can be induced by several
different mechanisms in vivo. First, infectious agents
containing homologous HSP60 proteins could induce an
anti–self-immune response through molecular mimicry in
susceptible individuals.16 Additionally, vaccination (par-
ticularly with heat-inactivated bacteria) may contribute to
the development of anti-HSP antibodies. Second, viral
infection might result in incorporation of HSP60, or at
least of HSP-derived peptides, into the envelope of the
budding virus.17 Arising from viral infections, HSP60
Figure 5. Dose-response curve of complement-mediated cyto-
toxicity. Conﬂuent HUVECs (EC in ﬁgure) in 96-well plates were
stressed at 42°C for 30 minutes followed by 90 minutes at 37°C
or kept without treatment. After 3 washes with RPMI, cells were
incubated with 5 mCi
51Cr in 60 mL medium at 37°C for 1.5
hours. After 2 further washes, antibodies (Abs) in 100 mL
medium were added at 37°C for 7 hours in presence of 50 mL
guinea pig serum as source of complement. After incubation,
supernatant radioactivity was determined in gamma counter.
Values are means of several experiments, each performed in
triplicate. *Signiﬁcant effect of puriﬁed anti-HSP antibodies on
heat-stressed endothelial cells compared with unstressed cells
or monoclonal control antibodies (P,0.01).
Figure 6. Comparison of complement-mediated cytotoxicity on
heat-stressed and unstressed endothelial cells (EC). Procedure
used in this experiment is similar to that described in Figure 5.
Cytotoxic effect of puriﬁed anti-HSP antibodies (Ab) could be
blocked by addition of GroEL. *Signiﬁcant difference from
unstressed cells (P,0.01).
Figure 7. Comparison of antibody-mediated cytotoxicity
between aortic endothelial cells and HUVECs. Human aortic
cells (A) and HUVECs (B) were cultivated and treated in parallel,
and cytotoxicity assays were performed as described in Figure
5. Values are mean6SD of 3 independent experiments. Note
that there is no signiﬁcant difference in
51Cr release between
arterial cells and HUVECs. Ab indicates antibodies. *Signiﬁcant
difference from unstressed cells (P,0.05).
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alteration or posttranslational modification.18 Third, expo-
sure to endogenous HSPs or mimicry proteins might
induce immune reactions against HSP60, or endogenous
HSPs might interact with other immunogenic proteins.19
Proteins of the HSP60 family were considered to be
located intracellularly in mitochondria only, where they
facilitate protein translocation and act as chaperones pro-
tecting proteins from harmful enzymatic attacks during
folding. Accumulating evidence now points to an addi-
tional surface location of HSP60 proteins on not only
eukaryotic20,21 but also prokaryotic cells, such as H pylo-
ri.22 Immune reactions against HSPs could therefore pro-
vide a general basic level of protection and limit the spread
of infections by acting as an initial defense mechanism that
immediately interacts with microbial invaders. In contrast
to this benefit, the risk of autoimmunity must be taken into
consideration, because HSPs are also induced, eg, on
endothelial cells by other exogenous and endogenous
stimuli. The endothelium, as a barrier between blood and
underlying cells, is subjected to continuous mechanical
stress from blood pressure and acute or chronic injury from
toxins, such as LPS and importantly oxidized LDL, a
known risk factor in atherosclerosis.23 These stressors and
many others, such as cytokines24 and fever, all induce or
augment HSP production by the arterial endothelium to
prevent cell damage and maintain homeostasis in the
vessel wall.25 Temperatures of 42°C, as used in our
experiments, are indeed encountered in a setting of infec-
tion. They are rarely achieved at the body core but might
be reached in an inflamed atherosclerotic lesion. Thus,
preexisting antibodies and HSP60-specific T cells could
react with overexpressed HSP60 components in athero-
sclerotic lesions,26,27 causing endothelial14 and macro-
phage injury28 and subsequently contributing to the initi-
ation and perpetuation of inflammation.29 The in vitro
phenomenon of anti-HSP serum antibodies also exerting a
weak cytotoxic effect on unstressed endothelial cells may
be explained by a basal level of HSP60 expression,
particularly because in vitro culture is itself stressful to
cells compared with in vivo conditions.14
Because persistent chlamydial infections are associated
with decreased expression of protective antigens, such as
the major outer membrane protein and LPS, but an
abundance of the immunopathogenic HSP60,30 they may
contribute to the elevated serum antibody levels against
mHSP65 found in patients with clinically asymptomatic
carotid atherosclerosis.11 In fact, our data provide evidence
that sera with high titers to mHSP65 are highly reactive
against C pneumoniae. Additionally, cHSP60 synthesis in
infected cells is likely to be accompanied by an increase in
human HSP60 production, because chlamydial infection
extensively stresses host cells.31 cHSP60 appears to be the
key antigen in eliciting a delayed hypersensitivity reaction
of the host in blinding trachoma or fallopian tube obstruc-
tion, resulting in severe tissue damage from C trachomatis
infections with interesting similarities to atherosclerosis.32
Immunopathology plays a decisive role in chlamydial
disease, but anti-HSP60 antibody–mediated immunity may
be a possible general link between infections and
atherogenesis.
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